Zolgensma Gene Therapy

Zolgensma is a groundbreaking gene therapy designed to treat spinal muscular atrophy (SMA) in pediatric patients. This innovative treatment works by delivering a copy of the SMN gene to the patient’s cells, addressing the root cause of the disease. With its potential to significantly improve motor function and quality of life, Zolgensma represents a major advancement in biotechnology. This product is available under strict regulatory guidelines and is intended for use in specialized medical settings.